Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | FPR3 | P25089 | 1/20 | 0.40 |
| ▸ | FPR2 | P25090 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | EBP | Q15125 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31442406 | 0.93 | TSHR (0.50) | TSHRSMN1; SMN2PAOXGLAFPR3 | |
| SCHEMBL11570934 | 0.92 | TSHR (0.58) | TSHRSMN1; SMN2PAOXGLAFPR3 | |
| SCHEMBL26528338 | 0.89 | PAOX (0.56) | TSHRSMN1; SMN2PAOXGLAFPR3 | |
| SCHEMBL12323784 | 0.85 | TSHR (0.50) | TSHRSMN1; SMN2PAOXGLAFPR3 | |
| SCHEMBL15150928 | 0.85 | TSHR (0.54) | TSHRSMN1; SMN2PAOXGLAFPR3 | |
| SCHEMBL1856574 | 0.85 | SMN1; SMN2 (0.57) | TSHRSMN1; SMN2PAOXGLAFPR3 | |
| SCHEMBL13943130 | 0.84 | PAOX (0.56) | TSHRSMN1; SMN2PAOXGLAFPR3 | |
| SCHEMBL2127041 | 0.83 | SMN1; SMN2 (0.60) | TSHRSMN1; SMN2GLAFPR3FPR2 | |
| SCHEMBL11732584 | 0.83 | SMN1; SMN2 (0.60) | TSHRSMN1; SMN2GLAFPR3FPR2 | |
| SCHEMBL21068880 | 0.82 | TSHR (0.47) | TSHRSMN1; SMN2PAOXGLAFPR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3727355-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | AstraZeneca AB (SE) | 2020-10-28 | — | — | EP | disclosed |
| CN-111491623-A | Compounds and their use in the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2020-08-04 | — | — | CN | disclosed |
| US-20190194190-A1 | Compounds and Their Use in Treating Cancer | ASTRAZENECA PHARMACEUTICALS LP | 2019-06-27 | — | — | US | disclosed |
| US-20190194190-A1 | Compounds and Their Use in Treating Cancer | ASTRAZENECA PHARMACEUTICALS LP | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194190-A1 | Compounds and Their Use in Treating Cancer | F12, CCNY, CCNE1 | TSHR 687/4885SMN1; SMN2 1942/4885PAOX 2046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.